Abstract -Aims: To investigate the role of aminopeptidases in the pathways to peptides neurotransmission/neuromodulation ending in the actions of ethanol (EtOH) on the brain. Methods: The effects of EtOH on alanyl-, arginyl-, cystyl-, leucyl-and tyrosylaminopeptidase activities were studied under basal/resting and K +
INTRODUCTION
Ethyl alcohol (EtOH) is the most widely and frequently used psychoactive drug in modern society. Chronic alcoholism is associated with numerous degenerative and inflammatory disorders of the central nervous system (CNS) and other organ systems, besides its well known depressor effect on several inhibitory nervous centres (Stone, 1995; Tabakoff and Hoffman, 1987; Gonzales and Hoffman, 1991; Castoldi et al., 1998; Erickson, 1996; Fadda and Rossetti, 1998) .
The search for methods to treat EtOH tolerance and/or dependence has begun to focus on the role of specific interactions between EtOH and major neurotransmitter systems or second-messenger systems (Kiiamaa, 1990; Kuriyama and Ohkuma, 1990; Wozniak and Linnoila, 1992; Erickson, 1996; Koob et al., 1998; Dahchour and De White, 2000) . EtOH is also considered to produce a physical perturbation of the lipid matrix of neuronal membranes, possibly leading to changes in the activity of membrane-bound proteins (Rubin and Rottenberg, 1982; Guerri and Grisolia, 1983; Logan et al., 1983; Schaad et al., 1988; French, 1991; Bora and Lange, 1993; Fadda and Rossetti, 1998) . However, the action of EtOH on the CNS and the exact nature of alcoholism as pathological process are not well understood.
Aminopeptidases (APs) are generally zinc metalloenzymes, which hydrolyse peptide bonds near the N-terminal end of peptides and polypeptides. APs are considered as one of the main pathways to neuropeptide inactivation and/or peptide activation by the hydrolysis of their precursors (Barrett et al., 1998) . Alanyl aminopeptidase (AlaAP), leucyl aminopeptidase (LeuAP, aminopeptidase M) and tyrosyl-AP (TyrAP, enkephalinase) can hydrolyse bradykinins (Sanderink et al., 1988) and enkephalins (Schnebli et al., 1979; Wagner et al., 1981; Hersh, 1985; Berg and Marks, 1989) . These may also act as angiotensinases (Ahmad and Ward, 1990) . Arginyl aminopeptidase (ArgAP, aminopeptidase B) specifically hydrolyses basic N-terminal residues from peptides and arylamide derivatives (Barrett et al., 1998) . Exopeptidase activity has been implicated in the metabolism of methionineenkephalin (Johson and Hersh, 1990 ) and angiotensin III (Ahmad and Ward, 1990) . Endopeptidase activity is also thought to be involved in neurotensin metabolism (McDermott et al., 1988) . Cystyl aminopeptidase (CysAP, oxytocinase) has been reported to hydrolyse oxytocin and vasopressin (Itoh and Nagamatsu, 1995) . However, the neurochemical effects of EtOH on the functional activity of these neurotransmitter/ neuromodulatory systems are not fully understood. The present work was designed to study the effects of EtOH on aminopeptidase activities (AlaAP, ArgAP, CysAP, LeuAP and TyrAP) at synapse level under basal (resting) and K + -stimulated conditions. For this purpose, mouse frontal cortex synaptosomes and their supernatants were incubated in Ca 2+ -containing or Ca 2+ -free artificial cerebrospinal fluid (aCSF).
Synaptosome preparation
Synaptosomes were prepared as previously described (Martínez-Martos et al., 2000) and resuspended in a Ca +2 -containing or Ca +2 -free aCSF (116 mM NaCl, 5.4 mM KCl, 0.9 mM MgCl 2 , 0.9 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 1.8 mM CaCl 2 and 10 mM glucose; or the same with 1 mM EGTA instead of CaCl 2 ) at pH 7.2, to a final concentration of 0.5 mg/ml protein.
Synaptosomes were incubated (37ЊC, 15 min) under basal conditions (controls), in presence of 25, 50 and 100 mM EtOH, under depolarized conditions (25 mM K + ), and in presence of 25, 50 and 100 mM EtOH under depolarized conditions. After incubation, synaptosomes were precipitated and the resulting supernatant was used to detect AlaAP, ArgAP, CysAP, LeuAP and TyrAP activities. The synaptosomes were again resuspended in Ca 2+ -containing or Ca
2+
-free aCSF at 37ЊC to determine aminopeptidase activities. (LeuNNap) and L-tyrosyl-β-naphthylamide (TyrNNap) substrates, in accordance with previously described methods (Greenberg, 1962; Schwabe and McDonald, 1977) . The use of arylamide substrates to assay aminopeptidase activity is well established. Briefly, 20 µl of synaptosomes or supernatant were incubated with 50 µl of 100 µM AlaNNap, ArgNNap, CysNNap, LeuNNap or TyrNNap substrate solution for 30 min at 37ЊC. The reactions were stopped by adding 50 µl of acetate buffer 0.1 M, pH 4.2 containing 2% Fast Garnet GBC salt. The amount of β-naphthylamine released through the enzymatic activity was coupled to the GBC salt, yielding a coloured compound that can be measured spectrophotometrically at 550 nm.
Aminopeptidase activities
Specific enzymatic AlaAP, ArgAP, CysAP, LeuAP and TyrAP activities (n = 11) were expressed as nmol of AlaNNap, ArgNNap, CysNNap, LeuNNap or TyrNNap hydrolysed per min per mg protein, using a standard β-naphthylamine curve determined under the same conditions. Proteins were also measured in triplicate using a standard curve for bovine serum albumin (BSA).
Statistical analysis
We used one-way analysis of variance (ANOVA) to analyse differences among the groups. Post hoc comparisons were made using the Newman-Keul's test; comparisons with P < 0.05 were considered significant.
RESULTS

Effects of EtOH on AlaAP activity
In the synaptosomes and under basal conditions, EtOH inhibited AlaAP activity (P < 0.01) in presence of Ca 2+ in a concentration-dependent manner (Fig. 1A) . In absence of Ca 2+ , Fig. 1 . Effects of 25, 50 and 100 mM ethanol on AlaAP of synaptosomes and supernatant in presence (A and C) or absence (B and D) of Ca 2+ . Results are expressed in nanomoles of Ala-β-naphthylamide hydrolysed per min and per mg of protein (mean ± SEM; n = 11; **P < 0.01).
only the highest concentration of EtOH (100 mM) inhibited this activity (P < 0.01) (Fig. 1B) . In the supernatant, AlaAP activity was increased (P < 0.01) by EtOH in presence of Ca 2+ (Fig. 1C ) but was not modified by EtOH in its absence (Fig. 1D) .
In synaptosomes under K + -stimulated conditions without EtOH, AlaAP activity decreased (P < 0.01) in both presence ( Fig. 2A) and absence of Ca 2+ (Fig. 2B ). In the supernatant, AlaAP activity increased (P < 0.01) in presence of Ca 2+ ( Fig. 2C ) but was unchanged in its absence (Fig. 2D) .
In synaptosomes under K + -stimulated conditions in presence of Ca 2+ , EtOH decreased AlaAP activity (P < 0.01) in a biphasic manner according to the EtOH concentration used ( Fig. 2A) . In absence of Ca 2+ , 50 and 100 mM EtOH decreased AlaAP activity (P < 0.01) but 25 mM EtOH significantly (P < 0.01) increased it (Fig. 2B) . In the supernatant, EtOH inhibited (P < 0.01) the K + -stimulated increase in AlaAP activity in presence of Ca 2+ (Fig. 2C) . In absence of Ca 2+ , 50 and 100 mM but not 25 mM EtOH significantly (P < 0.01) decreased AlaAP activity (Fig. 2D) .
Effects of EtOH on ArgAP activity
In synaptosomes under basal conditions, EtOH showed a biphasic effect depending on the concentration used. Thus, 25 and 100 mM EtOH inhibited ArgAP activity (P < 0.01) in presence of Ca 2+ , whereas 50 mM EtOH increased it (P < 0.01) (Fig. 3A) . In absence of Ca 2+ , EtOH inhibited ArgAP activity (P < 0.01) in a concentration-dependent manner (Fig. 3B) . In the supernatant, ArgAP activity decreased (P < 0.01) at all EtOH concentrations in presence of Ca 2+ (Fig. 3C ). In absence of Ca 2+ , 25 and 100 mM EtOH increased this activity (P < 0.01 and P < 0.05, respectively), whereas 50 mM EtOH did not (Fig. 3D) .
In synaptosomes under K + -stimulated conditions without EtOH, ArgAP was not modified in presence of Ca 2+ (Fig. 4A ). In absence of Ca 2+ , ArgAP activity significantly (P < 0.01) increased (Fig. 4B) . In the supernatant, ArgAP activity increased in presence of Ca 2+ (P < 0.05; Fig. 4C ) but decreased (P < 0.01) in its absence (Fig. 4D) .
In synaptosomes under K + -stimulated conditions, 50 and 100 mM but not 25 mM EtOH decreased ArgAP activity (P < 0.01) in presence of Ca 2+ (Fig. 4A) . In absence of Ca 2+ , 50 and 100 mM EtOH inhibited (P < 0.01) the K + -stimulated increase of ArgAP activity, whereas 25 mM EtOH did not modify it (Fig. 4B) . In the supernatant, in presence of Ca 2+ , 25 mM EtOH enhanced (P < 0.01) the K + -stimulated increase in ArgAP activity. However, 50 mM EtOH inhibited this increase and 100 mM EtOH decreased ArgAP activity (P < 0.01) to below control levels (Fig. 4C) . In absence of Ca 2+ , EtOH did not modify ArgAP activity (Fig. 4D ), blocking the K + -stimulated decrease in ArgAP activity.
Effects of EtOH on CysAP activity
In synaptosomes under basal conditions, EtOH inhibited CysAP activity (P < 0.01) to a variable degree depending on the EtOH concentration used in presence (Fig. 5A) or absence ( Fig. 5B) of Ca 2+ . In the supernatant, 50 and 100 mM but not 25 mM EtOH decreased (P < 0.01) CysAP activity in presence of Ca 2+ (Fig. 5C ). In absence of Ca 2+ , EtOH significantly (P < 0.01) decreased CysAP activity at all concentrations used (Fig. 5D ).
In synaptosomes under K + -stimulated conditions without EtOH, CysAP activity was unchanged in presence of Ca 2+ ( Fig. 6A ) but was increased in its absence (P < 0.05; Fig. 6B ). In the supernatant, however, CysAP activity increased (P < 0.05) in presence of Ca 2+ ( Fig. 6C ) and decreased (P < 0.01) in its absence (Fig. 6D ).
In synaptosomes under K + -stimulated conditions, 50 and 100 mM but not 25 mM EtOH decreased CysAP activity in presence of Ca 2+ (P < 0.01; Fig. 6A ). In absence of Ca 2+ , 25 mM EtOH increased CysAP activity (P < 0.01) whereas 50 and 100 mM EtOH decreased it (P < 0.01; Fig. 6B ). In the supernatant, 25 and 50 mM EtOH increased CysAP activity (P < 0.01) in presence of Ca 2+ , but 100 mM EtOH completely inhibited the K + -stimulated increase in CysAP activity (Fig.  6C ). In absence of Ca 2+ , 25 and 50 mM EtOH did not modify the K + -stimulated inhibition of CysAP activity, whereas 100 mM EtOH completely blocked it (Fig. 6D ).
Effects of EtOH on LeuAP activity
In synaptosomes under basal conditions, EtOH showed a biphasic effect depending on the concentration used. Thus, 25 and 100 mM EtOH inhibited LeuAP activity (P < 0.01) in presence of Ca 2+ , whereas 50 mM EtOH increased it (P < 0.01; Fig. 7A ). Similar results were recorded in absence of Ca 2+ , although 50 mM EtOH did not increase LeuAP activity to above control levels (Fig. 7B ). In the supernatant, LeuAP activity decreased (P < 0.01) at all EtOH concentrations (P < 0.01) in both presence ( Fig. 7C ) and absence of Ca 2+ (Fig. 8D ). In synaptosomes under K + -stimulated conditions without EtOH, LeuAP activity was not modified in presence of Ca 2+ ( Fig. 8A ). In absence of Ca 2+ , LeuAP activity significantly increased (P < 0.01; Fig. 8B ). In the supernatant, LeuAP increased (P < 0.01) in presence of Ca 2+ ( Fig. 8C ) but decreased (P < 0.01) in absence of Ca 2+ (Fig. 8D ). In synaptosomes under K + -stimulated conditions, EtOH decreased LeuAP activity in a concentration-dependent manner (P < 0.01 for all concentrations) in presence of Ca 2+ (Fig. 8A ). In absence of Ca 2+ , 25 and 100 mM EtOH enhanced the K + -stimulated increase in LeuAP (P < 0.01) but 50 mM EtOH inhibited LeuAP activity (P < 0.01; Fig. 8B ). In the supernatant, in presence of Ca 2+ , 25 mM EtOH enhanced the K + -stimulated increase in LeuAP activity, whereas 50 mM EtOH inhibited this increase and 100 mM EtOH inhibited it to below control levels (P < 0.01; Fig. 8C ). In absence of Ca 2+ , 25 mM EtOH blocked the K + -stimulated decrease in LeuAP activity, with levels below control values (P < 0.01). However, 50 and 100 mM EtOH did not change the K + -stimulated inhibition of LeuAP (Fig. 8D) , maintaining values below control levels (P < 0.01).
Effects of EtOH on TyrAP activity
In synaptosomes under basal conditions, 25 and 100 mM but not 50 mM EtOH inhibited TyrAP activity (P < 0.01) in presence of Ca 2+ (Fig. 9A ). In absence of Ca
2+
, EtOH decreased TyrAP activity to a variable degree depending on the concentration of . Results are expressed in nanomoles of Cys-β-naphthylamide hydrolysed per min and per mg of protein (mean ± SEM; n = 11; *P < 0.05; **P < 0.01). EtOH used (Fig. 9B ). In the supernatant, EtOH significantly (P < 0.01) decreased TyrAP activity at all concentrations in both presence and absence of Ca 2+ ( Fig. 9C and D) . In synaptosomes under K + -stimulated conditions without EtOH, TyrAP activity decreased (P < 0.01) in presence of Ca 2+ (Fig. 10A) . However, TyrAP activity significantly increased (P < 0.01; Fig. 10B ) in absence of Ca 2+ . In the supernatant, 25 mM K + significantly (P < 0.01) increased TyrAP activity in presence of Ca 2+ (Fig. 10C ) but decreased it (P < 0.01) in absence of Ca 2+ (Fig. 10D ). In synaptosomes under K + -stimulated conditions, EtOH decreased TyrAP activity in presence of Ca 2+ at all concentrations used (P < 0.01; Fig. 10A ). In absence of Ca 2+ , 25 mM EtOH did not change the K + -stimulated increase in TyrAP activity but 50 and 100 mM EtOH decreased it significantly (P < 0.01 and P < 0.05, respectively; Fig. 10B ). Finally, in the supernatant, in presence of Ca 2+ , EtOH inhibited the K + -stimulated increase in TyrAP activity to a variable degree depending on the concentration used (Fig.  10C) . In absence of Ca 2+ , however, EtOH increased TyrAP activity at all concentrations (P < 0.01), blocking the inhibition induced by 25 mM K + alone (Fig. 10D) .
DISCUSSION
EtOH has long been thought to act at the molecular level by disordering biological membranes, increasing their fluidity and possibly perturbing the functions of the proteins embedded within the membrane. However, the doses required to produce such effects have always been high (>50 mM), and recent evidence has accumulated to suggest that lower doses of EtOH may act directly upon proteins and, more specifically, upon ligand-gated channels (GABA and glutamate The changes in activity induced by EtOH may be due to a direct effect of this drug and/or its metabolites on AP activities or to their effects on the constituents of synaptosome membranes. It is well known that EtOH increases the fluidity of the membrane and changes its lipid composition, impairing various membrane-bound functions (Diamond and Gordon, 1997) . EtOH also induces neurotransmitter release in unstimulated synaptosomes regardless of the extrasynaptosomal Ca 2+ concentration, which indicates a redistribution of intracellular Ca 2+ . EtOH induces Ca 2+ release in a concentration-dependent manner over the 30-500 mM range, indicating that the stimulatory effects of EtOH on the basal/resting release of neurotransmitters may be due to the microsomal release of Ca 2+ (Shah and Pant, 1988) . These Ca 2+ movements may be related to the modulator effects of EtOH on AP supernatant activities. In fact, a mechanism for AP release has been proposed that is similar to the classical neurotransmitter release (Mayas et al., 2000a The increase of AP activities in the supernatant in presence of Ca 2+ may probably be the result of the release of the enzymes from the synaptosomes to the incubation medium, as previously described for the enzyme pyroglutamyl aminopeptidase (Mayas et al., 2000a It has been demonstrated that the in vitro addition of EtOH to mouse or rat synaptosomes inhibits the depolarizationdependent uptake of Ca 2+ without affecting uptake under nondepolarizing conditions. These results suggest that the known inhibitory effects of EtOH on the stimulated release of neurotransmitters may be mediated by the inhibition of the depolarization-dependent influx of Ca 2+ (Canda et al., 1995) . The block of synaptosomal voltage-dependent Ca 2+ channels may be responsible for these effects of EtOH on AP activities. Furthermore, although some concentrations of EtOH cooperate to avoid the release of the enzyme from the synaptosomes, others increased the enzymatic activity, probably due to intrasynaptosomal Ca 2+ redistribution induced by EtOH, as discussed above.
Taken together, our results show general inhibitory or biphasic effects of EtOH on AP activities under basal/resting and K + -stimulated conditions in a physiological environment containing Ca 2+ . Thus, the effects of EtOH can be considered the sum of specific interactions with multiple neurotransmitter/ neuromodulatory systems (dopamine, serotonin, GABA, glutamate and neuropeptides) (Eckardt et al., 1998; Koob et al., 1998) . However, the differential contribution of each neurotransmitter/neuromodulatory system at diverse EtOH concentrations may constitute the neurochemical basis of the dose-dependency effects of EtOH. In any case, these modulator effects of EtOH on AP activities are not related to EtOH-induced neurotoxic events, as previously demonstrated under our experimental conditions (Mayas et al., 2000b) . As discussed above, the modulator effects of EtOH on AP may also be due to a direct effect of EtOH and/or its metabolites on AP activities or to their effects on the constituents of synaptosome membranes. An early hypothesis to explain the CNS effects of EtOH suggested that EtOH, as an amphipathic molecule, produces a physical perturbation of the lipid matrix of neuronal membranes, possibly leading to changes in the activity of membrane-bound proteins. However, at pharmacologically relevant concentrations, the effect of EtOH on the fluidity of membrane bulk lipids is very small, or undetectable, and changes are no greater than would be expected with daily variations in body temperature (Rubin and Rottenberg, 1982; Guerri and Grisolia, 1983; Logan et al., 1983; Schaad et al., 1988; French, 1991; Tabakoff et al., 1996; Eckardt et al., 1998) . More recently, the existence of neuronal proteins highly sensitive to EtOH has been proposed, called 'receptive elements for ethanol' (REE) (Tabakoff and Hoffman, 1987; Mihic et al., 1997) . Among these REE are multi-subunit, membrane-bound protein complexes, including ligand-gated ion channels and proteins involved in neuronal signal transduction processes. It could be argued that neuropeptidedegrading AP activities are REE.
There is scant knowledge about the influence of EtOH on CNS AP activities. Witek and Kolataj described an inhibitory effect of EtOH on AlaAP and LeuAP activities in mouse brain lysosomal fraction, related to the duration and concentration of the EtOH administered. Similar results were described in liver, kidney and muscle (Witek and Kolataj, 1999) . However, the effect of EtOH on serum AP activities is better known. Brecher et al. reported the potent inhibitory effect on serum AlaAP and ArgAP of acetaldehyde (the major metabolic product of EtOH metabolism) but not of EtOH itself (Brecher et al., 1996) . These results suggest that the modifications in AP activities described in the present work may be due less to the action of EtOH and more to that of acetaldehyde, which could be generated as a consequence of EtOH metabolism (Veloso et al., 1972; Tabakoff and von Wartburg, 1975; Zimatkin and Dietrich, 1997) . However, further studies are required to clarify the influence of acetaldehyde on AP activities. EtOH administration also exerts a synergistic effect on the activities of brush border membrane enzymes and on liver morphology. The increase in specific brush border enzyme activities in the excluded loop results from a major protein loss observed in this segment (Raul et al., 1982) . In the liver, AlaAP and pyroglutamyl aminopeptidase activities showed significant increases at 24 h compared with pair-fed controls. In contrast, dipeptidyl-aminopeptidase II, cathepsins B, L and H showed significant decreases. Protease activities in skeletal muscle did not change significantly at 24 h (Reilly et al., 2000) .
The EtOH-induced changes in AP activities described in the present work are of interest because they may reflect the functional status of their corresponding endogenous substrates, which have important functions in several neurotransmitter/ neuromodulatory systems. However, it should be noted that APs have usually been described as non-specific enzymes capable of hydrolysing a broad spectrum of endogenous peptide substrates and arylamide derivatives to different degrees. However, our results with synaptosomes demonstrate different patterns of AP activities in response to the addition of EtOH to the aCSF. AP activities may be highly specific to their native substrates and may modulate them strictly in accordance with their surrounding microenvironment.
Opioid peptides, such as enkephalins, can be hydrolysed by AlaAP and LeuAP (ApM), ArgAP (ApB) and TyrAP (enkephalinase) (Schnebli et al., 1979; Wagner et al., 1981; Hersh, 1985; Berg and Marks, 1989) . The opioidergic (β-endorphin, enkephalin and dinorphins) system is known to be involved in EtOH abuse (Blum et al., 1989) . Chronic administration of EtOH to rats showed an increase in leuenkephalin in the cortex and in met-enkephalin in the striatum, medulla oblongata and thalamus. However, prolonged alcoholization led to a decreased concentration of leu-and met-enkephalins in the striatum, thalamus and medulla oblongata and to an increased concentration of leu-enkephalin in the cerebral cortex (Burov et al., 1983) . In addition, enkephalin levels increased in all brain regions of offspring from both maternally and paternally exposed rats (Nelson et al., 1988) . Our results support these observations, because the inhibitory effects of EtOH on these AP activities would increase the level of their substrates, potentiating their action. On the other hand, it has been shown that under K + -stimulated conditions, repeated EtOH administration reduces the release of met-enkephalin from hypothalamic slices. Therefore, repeated EtOH treatment may lead to changes in specific neuron population sensitivity to the depolarizing effect of potassium (Przewlocka and Lason, 1991) . This altered sensitivity may also be the consequence of a differential behaviour of the opioid receptors. Thus, a particular sensitivity to chronic EtOH administration of the δ opioid receptor but not the µ opioid receptor has been proposed (Przewlocka and Lason, 1990) . In the present work, we showed an inhibitory effect of EtOH on K + -stimulated AP activities, especially on TyrAP activity (enkephalinase) in presence of Ca 2+ , which may reflect these processes. Our results also support the hypothesis that neuropeptides and their degrading enzymes are released together.
Other important neurotransmitter/neuromodulatory systems involved in EtOH tolerance and dependence are those mediated by oxytocin and vasopressin, which are susceptible to hydrolysis by CysAP (Itoh and Nagamatsu, 1995) . Oxytocin is a neurohypophyseal neuropeptide synthesized in the brain and released at the posterior pituitary and in the CNS. This neuropeptide is associated with different adaptive processes of CNS related to EtOH addition and tolerance. In the CNS, EtOH tolerance appears to be a combined process, with both cellular and behavioural components. Tolerance to EtOH has been shown to involve learning, because animals displayed tolerance only in an environment where EtOH had previously been presented and not in a novel environment (Kovács et al., 1998) . Development of rapid tolerance to the hypothermic effect of EtOH has been proposed as a reliable model for investigating the above phenomenon (Szabó et al., 1985 (Szabó et al., , 1987 . The central administration of oxytocin blocked the development of rapid tolerance to EtOH (Szabó et al., 1989) . This supports the theory that oxytocin acts on CNS mechanisms to influence adaptive responses to EtOH. The central administration of oxytocin at doses that inhibit the development of rapid tolerance to EtOH increased norepinephrine levels in the hypothalamus, dopamine levels in the striatum and medulla oblongata, and serotonin levels in the hippocampus and striatum (Szabó et al., 1988) . The mechanism of EtOH action on CNS neurotransmission is unclear. Serotoninergic and dopaminergic neurotransmission appear to be primarily altered during the inhibition of tolerance development by oxytocin (Szabó et al., 1989) . These and other results suggest that several neuropeptides modulate the response to EtOH. In the case of oxytocin, adaptive components of drug addiction are primarily affected, with the neuropeptide inhibiting the development of EtOH tolerance. EtOH acts on the CNS through various mechanisms, and oxytocin inhibits adaptive CNS processes in response to EtOH. Because oxytocinergic neuronal transmission and CNS oxytocin receptors are supposedly involved in these effects, it has been hypothesized that central nervous oxytocinergic neurons are integral elements of the brain's adaptive response to EtOH. The adaptive response of the CNS to repeated administration of EtOH leads to tolerance and dependence. Activation of brain oxytocinergic neurotransmission under these circumstances may represent a physiological counterbalance mechanism that may be of functional significance, especially in early neuronal adaptation, and may prevent the rapid onset of EtOH tolerance and dependence (Kóvacs et al., 1998) . Our results showed an important inhibition of EtOH on CysAP activity, which may potentiate oxytocin effects.
Regarding vasopressin, it has been demonstrated that this neuropeptide may influence the development of functional tolerance and/or physical dependence on EtOH. This and other peptides were previously shown to influence learning and/or memory. However, other analyses revealed differences in the structural requirements for the maintenance of EtOH tolerance compared with the facilitation of memory processes. Therefore, these phenomena may represent CNS adaptive processes that are subserved by different mechanisms or are differentially sensitive to particular peptides (Hoffman and Tabakoff, 1981) . In any case, these effects seem to be modulated through vasopressin V1 receptor activation and second messenger production (Briley et al., 1994) . Intracerebroventricular injection of vasopressin in mice resulted in a substantial increase in mRNA for the protooncogene c-fos. Increased c-fos expression has been hypothesized to play a role in neuroadaptation, which could be important for vasopressin effects on EtOH tolerance (Giri et al., 1990) . Our results also agree with a potentiation of vasopressin by EtOH, through the inhibition of its degrading AP by EtOH. These observations might provide useful insights into the way in which an endogenous neuronal peptide modulates adaptive functions in the CNS by acting through its own receptors and also by modifying the efficacy of a classical neuronal transmitter system. After their synthesis and release, endogenous neuropeptides are only present in the brain and body fluids for a few minutes, similar to the biological half-life of exogenously administered neuropeptides. However, their effects on addiction can be detected long after peptide release/administration. Thus, neuropeptides set into motion various secondary events in the CNS that maintain all these changes viable, probably through molecular mechanisms such as changes in gene expression. In fact, it has been demonstrated that EtOH administration induces gene expression changes that are responsible for cellular responses of tolerance and dependence (Mackler and Eberwine, 1991) . To our knowledge, there is no available information regarding the effects of EtOH on AP gene expression. The chronic administration of EtOH significantly decreased the total number of vasopressin and other neuropeptide-containing neurons (Madeira et al., 1997) . Therefore, vasopressin may influence other neurotransmitter/ neuromodulatory systems.
Finally, ArgAP (ApB) and AlaAP and LeuAP (ApM) activities also participate in the brain renin-angiotensin system (bRAS) (Ganong, 1995) , considered to be the pathway for synthesis of locally produced angiotensin II (Ang-II) in the brain (De Gasparo et al., 1994; Sim et al., 1994) . The pressor peptide Ang-II is converted to the heptapeptide angiotensin III (Ang-III) by aminopeptidase A (angiotensinase), which is primarily responsible for cleaving aspartic acid from the N-terminus of Ang-II (Sakura et al., 1983; Rich et al., 1984) . Ang-III is further converted to the hexapeptide angiotensin IV (Ang-IV) by ArgAP and also by ApM, which cleaves arginine from the N-terminus (Abhold and Harding, 1988) . Ang-III and Ang-IV are both biologically active (Wright and Harding, 1995) . Chronic EtOH abuse may lead to an altered regulation of the local brain blood flow and/or of the fluid and electrolytic balance (Mungall et al., 1995) by stimulating bRAS activity, and the CNS is especially sensitive to these phenomena, which cause a variety of vascular and cellular changes (Amenta et al., 1996) . The inhibitory effects of EtOH on ArgAP and ApM activities suggest the existence of high levels of Ang-III that exert a major pressor effect in the brain, probably due to its action on AT 1 receptors (De Gasparo et al., 1994) . It has also been suggested that the EtOH metabolite acetaldehyde increases the synthesis rate of Ang-I and also inhibits aminopeptidase A activity (Brecher et al., 1996) , which contributes to the hypertension observed in alcoholics (Thevananther and Brecher, 1994) . Previous studies of mouse cortex synaptosomes at our laboratory demonstrated that EtOH inhibits aminopeptidase A (Mayas et al., 2000c (Mayas et al., , 2001 ). It has also been reported that acetaldehyde inhibits AlaAP activity, increasing the pressor effect of Ang-III (Brecher et al., 1996) . Our results also support this hypothesis because we show an inhibitory effect of EtOH on AlaAP, ArgAP and LeuAP activities. Therefore, the limited degradation of Ang-II/Ang-III by AP activities as a consequence of EtOH (or acetaldehyde) effects may play a major role in increasing blood pressure at brain level.
In conclusion, EtOH-induced changes in AP activities at the synapse level do not reflect possible tissue damage. However, EtOH may modulate the function of several active peptides that act in the CNS through the enzymes involved in degrading them, probably as a result of complex interactions between EtOH and CNS neurotransmitter/neuromodulatory systems involved in EtOH tolerance and/or dependence.
